Building a shared database of patients with IgA nephropathy in China
Collects and organizes health records from patients with IgA nephropathy across several hospitals.
Plain-language title generated from the registry record
Registry title: The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Ruijin Hospital Shanghai Jiaotong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT04858724
- Record updated
- 18 August 2026
- Original description
1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis. 3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation. 4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.Read full original descriptionShow less
Construction of a Multi-center Database for Primary IgA Nephropathy
1. Establish an IgAN cohort collaboration group and expert committee to carry out registration research. 2. Construct IgAN structured data set standards, formulate structured data collection templates of diagnosis and treatment , and establish multi-center data integration systems on this basis. 3. Establish a standardized IgAN database for combined Hospital Information System and the big data platform of the Medical Federation. 4. Develop IgAN database managements and open standards for data sharing, and carry out high-quality clinical or basic research.
Inclusion: No age limit, no gender limit; Kidney biopsy confirmed primary IgA nephropathy; Sign the informed consent form voluntarily.
Exclusion: IgA nephropathy is secondary to systemic diseases such as systemic lupus erythematosus and allergic purpura; IgAN is clinically diagnosed but not confirmed by pathology; The patient refuses to participate; Patients judged by other investigators to be unsuitable for inclusion in the study.